Investigating SARS-CoV-2 and the Vaccine's Global Impacts of Cardiac Complications

The COVID-19 pandemic, initiated by SARS-CoV-2 in early 2020, has profoundly impactedglobal health, particularly cardiovascular disease (CVD). This research paper examines the linkbetween COVID-19 and CVD, highlighting the increase in CVD rates due to the inflammatoryresponse triggered by the virus. Inflammation affects the heart's lining, muscle, and surroundingtissue, potentially leading to atherosclerosis, where plaque buildup can cause blood clots, heartattacks, and strokes (Heart Disease and Stroke). During SARS-CoV-2 infection, the immunesystem's pro-inflammatory cytokines exacerbate inflammation, impacting heart function andpromoting heart disease. Furthermore, an analysis of data from the Centers for Disease Controland Prevention website CDC Wonder revealed that CVD rates post-COVID-19 increased in2019-2021. While Oxford-AstraZeneca's vaccine, Vaxzevria, can trigger blood clotting, otherstudies show that various vaccinations, such as Johnson-Johnson, Pfizer, and Moderna, canreduce cardiovascular complications by decreasing inflammation and infection rates (Paknahadet al. 173).